Bioteke Corporation, a leading high-tech manufacturer specializing in molecular diagnostics and rapid detection, particularly in nucleic acid extraction, announces a strategic partnership with Landcent, a health-focused organization dedicated to advancing the right to health for individuals with limited access.
Established in 2005, Beijing-based Bioteke has become a prominent developer of molecular diagnostic instruments and reagents. With its main manufacturing facility in Wuxi City, Jiangsu province, the company has six research and development centers across China, five production sites totaling 42000 square meters, two research fields, and holds 44 patents and 12 software copyrights. Recognized as a National High-Tech Enterprise, Bioteke has achieved ISO13485 certification and various other product qualification certificates.
Landcent is dedicated to advancing the right to health for individuals with limited or no access, by accelerating the fight against diseases of poverty, including Neglected Tropical Diseases (NTDs). Funded in part by The Bill & Melinda Gates Foundation, Landcent has secured over €18 million for the development of next-generation insecticidal treated bed-nets, indoor residual sprays, and other vector control tools. With its first product WHO pre-qualified product slated to enter the market by 2025, Landcent aims to protect over 180 million people from malaria by 2030.
The collaboration between Bioteke and Landcent commenced in 2020 during the global pandemic. Leveraging their combined expertise in product development and supply chain management, the partnership distributed high-quality consumables, kits, and reagents to frontline workers. These critical supplies reached organizations such as the NHS, World Vision, and other global donors.
In 2022, Bioteke and Landcent strengthened their partnership to further accelerate the fight against NTDs. Bioteke, as the manufacturer, and Landcent, as the commercialization partner, will work together to provide essential diagnostic and testing commodities to Low- and Middle-Income Countries (LMICs). The collaboration's guiding principles are to ensure high quality and affordability in their products and services.
“Even as renewed initiatives are underway to formulate new national diagnostics strategies for LMICs, we are excited to proactively set up essential supply chains to fulfill emerging demands. We are delighted to collaborate with the likes of Bioteke, a distinguished high-quality manufacturer, who shares our value of making diagnostics affordable and widely available.” - Erik Coumou, VP, Life Sciences Partnerships, Landcent Europe B.V.
For more information, visit: